Patientenforschung
Anmelden
Alle Studien
RekrutierungPhase I/IIInterventionell

A study to learn how the study medicine called PF-07868489 is tolerated and acts in people with pulmonary arterial hypertension

This research study is investigating a new medicine called PF-07868489 for people living with pulmonary arterial hypertension (PAH). PAH is a serious condition affecting the blood vessels in the lungs, making everyday activities difficult. This study aims to understand how safe the new medicine is and how the body reacts to it. It’s a first-step study (Phase I/II) to help researchers learn more before it can be widely used. Participants must be adults with a confirmed diagnosis of PAH and meet certain health requirements. While the study might not directly benefit participants, it could help develop new treatments for PAH in the future.

Auf einen Blick

Status
Rekrutierung
Phase
Phase I/II
Sponsor
Pfizer Europe MA EEIG
Einschreibeziel
94
Starten
07 Jun 2025
Geschätzte Fertigstellung
12 Jan 2027
Pulmonary arterial hypertension

Worum geht es in dieser Studie?

This study is exploring a new medicine called PF-07868489. It's for people with a condition called pulmonary arterial hypertension, often shortened to PAH. PAH causes high blood pressure in the arteries leading from your heart to your lungs, which makes your heart work harder and can make you feel breathless and tired. The main goal of this study is to see if this new medicine is safe and how well people tolerate it. Researchers also want to understand how the medicine works inside the body, which is important for developing effective treatments in the future.

This is an early-stage study, known as Phase I/II. This means it's one of the first times the medicine is being tested in people with PAH. Researchers need to gather important information about its safety and effects before it can move on to larger studies. The study information doesn't say exactly what taking part will involve day-to-day, but generally, early studies like this involve close monitoring of your health.

Taking part in studies like this is really important because it helps scientists learn more about new medicines. Even if a new medicine doesn't fully help a participant in the study, the information gathered can still be very valuable for developing better treatments for future patients with PAH.

Wichtige Erkenntnisse

  • It's a study for a new medicine for pulmonary arterial hypertension (PAH).
  • The main goals are to check the medicine's safety and how it works.
  • It's an early-stage study, so direct benefits might not be known yet.
  • Participants must be adults with confirmed PAH and meet specific health criteria.
  • Taking part involves clinic visits, tests, and closely monitoring your health.

Wer könnte berechtigt sein?

To join this study, you need to be at least 18 years old and have a confirmed diagnosis of pulmonary arterial hypertension (PAH). Your PAH should also fit certain types, such as those that are inherited or caused by certain drugs, or if it's linked to other conditions like connective tissue disease.

Your PAH would be classed as either 'WHO functional class II or III', which means it impacts your daily activities moderately or significantly. You would also need to have certain measurements from heart and lung tests, and already be on a stable treatment plan for your PAH. Your body mass index (BMI) should be between 16 and 35. You'll also need to be able to walk a certain distance in six minutes and shouldn't have other serious lung problems.

Before you can officially join, you'll have checks, including a special heart test called a 'right heart catheterisation'. You'll also need to be willing to follow all the study rules, including attending appointments and having specific tests. If you're pregnant, planning to become pregnant, or breastfeeding, you won't be able to take part.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Do you have a confirmed diagnosis of pulmonary arterial hypertension (PAH)?
  3. Are you able to attend all study appointments and follow instructions?
  4. Are you currently pregnant, planning to become pregnant, or breastfeeding?
  5. Are you using effective contraception if you are a woman of childbearing age?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

The detailed steps of what taking part involves aren't fully described yet. However, typically in studies like this, you would have regular hospital or clinic visits where you would receive the study medicine, have various health checks, and undergo tests like blood samples, heart scans, and lung function assessments. You would also have a right heart catheterisation at the start and end of the study.

The study medicine, PF-07868489, would likely be given as an injection. The full study is expected to run from November 2024 to January 2027.

Potenzielle Risiken und Vorteile

There's no information yet about direct benefits for people taking part in this study. However, contributing to research can help others with PAH in the future. As with any medicine, there are risks; taking the study drug might make you feel unwell, or it could cause allergic reactions like trouble breathing, swelling, or skin rashes. You might also have a reaction where the injection is given. A procedure called right heart catheterisation, which involves a thin tube being put into a vein, carries small risks like bleeding, abnormal heart rhythms, or lung collapse. You'll be closely monitored for any side effects, and you are free to leave the study at any time.

Standorte (4)

  • Hammersmith Krankenhaus
    Ungefähr
    London, Vereinigtes Königreich
  • Royal Brompton Hospital
    Ungefähr
    London, Vereinigtes Königreich
  • Royal Free Hospital
    Ungefähr
    London, Vereinigtes Königreich
  • Golden Jubilee National Hospital
    Ungefähr
    Clydebank, United Kingdom

Häufige Fragen

What is pulmonary arterial hypertension (PAH)?

PAH is a serious condition where blood pressure in the arteries going to your lungs becomes too high, making your heart work harder.

What is PF-07868489?

It's a new medicine being studied to see if it's safe and how it works for people with PAH.

What does 'Phase I/II' mean?

It's an early stage of research. Phase I checks safety, and Phase II starts looking at effectiveness and dosage in a small group of patients.

Will I get the actual medicine or a placebo?

The study mentions it's 'randomised, double-blind, placebo-controlled', meaning some will get the medicine and some a dummy drug, and neither you nor the doctors will know which.

What is a right heart catheterisation (RHC)?

It's a procedure where a thin tube is inserted into a large vein to measure pressures in your heart and lungs, helping doctors understand your condition better.

Wie Sie mehr erfahren können

Sarah Hughes

Sarah.Hughes@pfizer.com 447340276799 Offizielles Gerichtsprotokoll

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A study to learn how the study medicine called PF-07868489 i… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.